These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

120 related items for PubMed ID: 10530797

  • 41. Repeated antipsychotic drug exposure in developing rats: dopamine receptor effects.
    Moran-Gates T, Gan L, Park YS, Zhang K, Baldessarini RJ, Tarazi FI.
    Synapse; 2006 Feb; 59(2):92-100. PubMed ID: 16270300
    [Abstract] [Full Text] [Related]

  • 42. Dopamine agonistic potency of two novel prolactin release-inhibiting ergolines.
    Markó M.
    Eur J Pharmacol; 1984 Jun 01; 101(3-4):263-6. PubMed ID: 6468500
    [Abstract] [Full Text] [Related]

  • 43. Action of growth hormone release inhibitory hormone on prolactin release in rat pituitary cell cultures.
    Grant NH, Sarantakis D, Yardley JP.
    J Endocrinol; 1974 Apr 01; 61(1):163-4. PubMed ID: 4597758
    [No Abstract] [Full Text] [Related]

  • 44. S-16924 [(R)-2-[1-[2-(2,3-dihydro-benzo[1,4]dioxin-5-yloxy)-ethyl]- pyrrolidin-3yl]-1-(4-fluorophenyl)-ethanone], a novel, potential antipsychotic with marked serotonin1A agonist properties: III. Anxiolytic actions in comparison with clozapine and haloperidol.
    Millan MJ, Brocco M, Gobert A, Schreiber R, Dekeyne A.
    J Pharmacol Exp Ther; 1999 Mar 01; 288(3):1002-14. PubMed ID: 10027837
    [Abstract] [Full Text] [Related]

  • 45. S 16924 ((R)-2-[1-[2-(2,3-dihydro-benzo[1,4] dioxin-5-Yloxy)-ethyl]-pyrrolidin-3yl]-1-(4-fluoro-phenyl)-ethanone), a novel, potential antipsychotic with marked serotonin (5-HT)1A agonist properties: I. Receptorial and neurochemical profile in comparison with clozapine and haloperidol.
    Millan MJ, Gobert A, Newman-Tancredi A, Audinot V, Lejeune F, Rivet JM, Cussac D, Nicolas JP, Muller O, Lavielle G.
    J Pharmacol Exp Ther; 1998 Sep 01; 286(3):1341-55. PubMed ID: 9732398
    [Abstract] [Full Text] [Related]

  • 46. Comparison of clozapine and haloperidol on some autonomic and psychomotor functions, and on serum prolactin concentration, in healthy subjects.
    Pretorius JL, Phillips M, Langley RW, Szabadi E, Bradshaw CM.
    Br J Clin Pharmacol; 2001 Sep 01; 52(3):322-6. PubMed ID: 11560566
    [Abstract] [Full Text] [Related]

  • 47. Mechanism of the prolactin rebound after dopamine withdrawal in rat pituitary cells.
    Chen C, Zhang J, Israel JM, Clarke IJ, Vincent JD.
    Am J Physiol; 1993 Jul 01; 265(1 Pt 1):E145-52. PubMed ID: 8393290
    [Abstract] [Full Text] [Related]

  • 48. Amisulpride the 'atypical' atypical antipsychotic--comparison to haloperidol, risperidone and clozapine.
    Natesan S, Reckless GE, Barlow KB, Nobrega JN, Kapur S.
    Schizophr Res; 2008 Oct 01; 105(1-3):224-35. PubMed ID: 18710798
    [Abstract] [Full Text] [Related]

  • 49. Adenylate cyclase from various dopaminergic areas of the brain and the action of antipsychotic drugs.
    Clement-Cormier YC, Robison GA.
    Biochem Pharmacol; 1977 Sep 15; 26(18):1719-22. PubMed ID: 20110
    [No Abstract] [Full Text] [Related]

  • 50. GH in the dwarf dopaminergic D2 receptor knockout mouse: somatotrope population, GH release, and responsiveness to GH-releasing factors and somatostatin.
    García-Tornadú I, Rubinstein M, Gaylinn BD, Hill D, Arany E, Low MJ, Díaz-Torga G, Becu-Villalobos D.
    J Endocrinol; 2006 Sep 15; 190(3):611-9. PubMed ID: 17003262
    [Abstract] [Full Text] [Related]

  • 51. Octopamine and phenylethylamine inhibit prolactin secretion both in vivo and in vitro.
    Becú-Villalobos D, Thyssen SM, Rey EB, Lux-Lantos V, Libertun C.
    Proc Soc Exp Biol Med; 1992 Feb 15; 199(2):230-5. PubMed ID: 1741415
    [Abstract] [Full Text] [Related]

  • 52. The interaction of clozapine with the meta-chlorophenylpiperazine (mCPP) discriminative stimulus.
    Fiorella D, Rabin RA, Winter JC.
    Life Sci; 1996 Feb 15; 58(24):PL353-8. PubMed ID: 8649203
    [Abstract] [Full Text] [Related]

  • 53. Ethanol and estradiol modulate alternative splicing of dopamine D2 receptor messenger RNA and abolish the inhibitory action of bromocriptine on prolactin release from the pituitary gland.
    Oomizu S, Boyadjieva N, Sarkar DK.
    Alcohol Clin Exp Res; 2003 Jun 15; 27(6):975-80. PubMed ID: 12824819
    [Abstract] [Full Text] [Related]

  • 54. Morphological changes of pigeon crop-sac mucosa and pituitary lactotrophs after systemic and intraventricular administration of neuroleptic drugs.
    Nisticò G, Germanà G, Ciriaco E, Bronzetti B.
    Gen Comp Endocrinol; 1980 Jun 15; 41(2):180-9. PubMed ID: 6106624
    [No Abstract] [Full Text] [Related]

  • 55. Modulation by dopamine antagonists of DNA synthesis in the pituitary gland of the male rat.
    Jacobi JM, Lloyd HM.
    Neuroendocrinology; 1981 Aug 15; 33(2):97-100. PubMed ID: 7266775
    [Abstract] [Full Text] [Related]

  • 56. Dopamine dynamics during emotional cognitive processing: Implications of the specific actions of clozapine compared with haloperidol.
    Kawano M, Oshibuchi H, Kawano T, Muraoka H, Tsutsumi T, Yamada M, Inada K, Ishigooka J.
    Eur J Pharmacol; 2016 Jun 15; 781():148-56. PubMed ID: 27085900
    [Abstract] [Full Text] [Related]

  • 57. The effect of neuroleptics on brain tyrosine hydroxylase.
    Rayevsky KS, Mineyeva MF, Kudrin VS.
    Ann Ist Super Sanita; 1978 Jun 15; 14(1):89-96. PubMed ID: 40504
    [Abstract] [Full Text] [Related]

  • 58. Characterization of inhibition by risperidone of the inwardly rectifying K(+) current in pituitary GH(3) cells.
    Wu SN, Jan CR, Li HF, Chiang HT.
    Neuropsychopharmacology; 2000 Dec 15; 23(6):676-89. PubMed ID: 11063923
    [Abstract] [Full Text] [Related]

  • 59. Supersensitivity of pituitary dopamine receptors involved in the inhibition of prolactin secretion.
    Annunziato L, Quattrone A, Schettini G, Di Renzo G.
    Adv Biochem Psychopharmacol; 1980 Dec 15; 24():379-85. PubMed ID: 6105788
    [No Abstract] [Full Text] [Related]

  • 60. Dissociation of haloperidol, clozapine, and olanzapine effects on electrical activity of mesocortical dopamine neurons and dopamine release in the prefrontal cortex.
    Gessa GL, Devoto P, Diana M, Flore G, Melis M, Pistis M.
    Neuropsychopharmacology; 2000 Jun 15; 22(6):642-9. PubMed ID: 10788763
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.